Circio's circVec technology boosts gene therapy potency by up to 40x

Circio Holding ASA has unveiled new data demonstrating up to 40 times enhanced activity of its circVec-AAV vectors in the eye and heart. The latest circVec 3.2 design boosts gene expression by three times compared to previous generations, signaling a potential for over 10-fold viral dose reduction. This advancement could address critical safety and cost challenges in current AAV gene therapy.

The company’s first half year report highlights continued cost control and a secured financial runway until the end of 2025 through an extended financing commitment with Atlas Capital Markets. Circio is actively exploring new capital sources and partnerships with AAV expert companies.

The financial statements show a net loss of NOK 22.4 million for the first half of 2025, compared to a profit of NOK 41.7 million in the same period of 2024. Total operating expenses were NOK 20.4 million, reflecting a lean setup prioritizing R&D activities.